Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001

Source :: Plus Company Updates. November 15, 2023
Publication Year :: 2023
Abstract: ATLANTA: Alzamend Neuro, Inc. has issued the following news release: Alzamend Neuro, Inc. (Nasdaq: ALZN) ('Alzamend'), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's [...]

Subjects :: United States. Food and Drug Administration
Bipolar disorder -- Drug therapy
Medical research -- Health aspects
Medicine, Experimental -- Health aspects
Drug approval -- Health aspects
Clinical trials -- Health aspects
Post-traumatic stress disorder -- Drug therapy
General interest
News, opinion and commentary

Tools